CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | alicyclic ketone |
|
Accession: | CHEBI:36132
|
browse the term
|
Definition: | A cyclic ketone in which the carbocyclic ring structure which may be saturated or unsaturated, but may not be a benzenoid or other aromatic system. |
Synonyms: | related_synonym: | alicyclic ketones |
|
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions |
ISO |
beta-thujone inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein]; beta-thujone inhibits the reaction [Choline results in increased activity of CHRNA7 protein] |
CTD |
PMID:28395994 |
|
NCBI chr 1:116,715,286...116,837,223
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
ISO |
beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
ISO |
beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
ISO |
beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,376,805...26,463,680
Ensembl chr10:26,374,694...26,464,346
|
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
affects expression |
ISO |
Camphor analog affects the expression of COL1A2 mRNA |
CTD |
PMID:24704097 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
EXP |
Camphor results in decreased activity of CYP2B1 protein |
CTD |
PMID:9242356 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
Camphor inhibits the reaction [CYP2B6 protein results in increased hydrolysis of Bupropion] |
CTD |
PMID:18611395 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Camphor binds to and results in increased activity of ESR1 protein |
CTD |
PMID:27633901 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
ISO |
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
ISO |
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
ISO |
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,376,805...26,463,680
Ensembl chr10:26,374,694...26,464,346
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Camphor inhibits the reaction [cinnamaldehyde results in increased activity of MPO protein] |
CTD |
PMID:21466812 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Camphor binds to and results in decreased activity of PGR protein |
CTD |
PMID:27633901 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
affects expression |
ISO |
Camphor analog affects the expression of RUNX2 mRNA |
CTD |
PMID:24704097 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
affects expression |
ISO |
Camphor analog affects the expression of SPARC mRNA |
CTD |
PMID:24704097 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
Lidocaine promotes the reaction [Camphor results in increased activity of TRPV1 protein] |
CTD |
PMID:18172555 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Trpv3 |
transient receptor potential cation channel, subfamily V, member 3 |
increases activity multiple interactions |
ISO |
Camphor results in increased activity of TRPV3 protein isopentenyl pyrophosphate inhibits the reaction [Camphor results in increased activity of TRPV3 protein] |
CTD |
PMID:21353389 |
|
NCBI chr10:57,883,546...57,915,865
Ensembl chr10:57,883,546...57,913,296
|
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 results in increased expression of CXCL2 protein 13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of CXCL2 mRNA] |
CTD |
PMID:21094227 PMID:21735453 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of GATA3 mRNA] |
CTD |
PMID:21735453 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of IL4 protein] |
CTD |
PMID:21735453 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR protein; 13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions |
ISO EXP |
13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein] 13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein 13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein] |
CTD |
PMID:12721327 PMID:15528449 PMID:16256979 |
|
NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression multiple interactions |
EXP |
9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of BDNF mRNA Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of BDNF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions increases expression |
EXP |
Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA]; NFE2L2 protein affects the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 2:56,893,992...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
NFE2L2 protein affects the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression |
EXP |
Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of NGF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions affects export affects glutathionylation increases transport |
ISO |
[ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein] ABCC1 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog ABCC1 protein affects the glutathionylation of 15-deoxy-delta(12,14)-prostaglandin J2 |
CTD |
PMID:14979731 PMID:21728338 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
affects export |
ISO |
ABCC3 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog |
CTD |
PMID:14979731 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACAA2 mRNA |
CTD |
PMID:34323617 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA |
CTD |
PMID:34323617 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]] |
CTD |
PMID:18278065 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2 |
CTD |
PMID:19997560 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:16611854 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BGLAP mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BIRC2 protein |
CTD |
PMID:15498850 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BIRC3 protein |
CTD |
PMID:15498850 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases cleavage |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of CASP3 protein [delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of CASP3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of CASP3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:11785780 PMID:15498850 PMID:16299251 PMID:23973622 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:15498850 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:15498850 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]] |
CTD |
PMID:12847270 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein] |
CTD |
PMID:15187150 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA] |
CTD |
PMID:23688403 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] |
CTD |
PMID:19429239 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNA2 protein |
CTD |
PMID:15729575 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNB1 protein |
CTD |
PMID:15729575 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCND3 protein |
CTD |
PMID:15729575 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNE1 protein |
CTD |
PMID:15729575 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDK2 protein |
CTD |
PMID:15729575 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CDKN1A 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1A protein |
CTD |
PMID:15254749 PMID:15729575 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1B protein |
CTD |
PMID:15729575 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CEBPA mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CFLAR protein |
CTD |
PMID:15498850 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of CHUK protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased phosphorylation of CHUK protein] |
CTD |
PMID:15498850 PMID:22245093 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEC mRNA |
CTD |
PMID:34323617 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of COL1A1 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]] |
CTD |
PMID:12604364 PMID:14998300 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of and results in increased activity of EGR1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of EGR1 mRNA] |
CTD |
PMID:12468449 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions increases expression |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Tretinoin] results in increased expression of FABP4 mRNA [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FABP4 mRNA |
CTD |
PMID:9543393 PMID:12021203 PMID:16573735 PMID:34323617 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of FAS mRNA |
CTD |
PMID:16712844 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; wortmannin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA] |
CTD |
PMID:11457450 PMID:11687581 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; [ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein |
CTD |
PMID:21728338 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression decreases expression multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GFAP 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of GFAP mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in decreased expression of GFAP mRNA] |
CTD |
PMID:15254749 PMID:15994020 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
ISO |
GSTM1 protein affects the metabolism of [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Glutathione] |
CTD |
PMID:14979731 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA]; Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein] |
CTD |
PMID:11600134 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hdac1 |
histone deacetylase 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC1 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC2 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr20:40,548,250...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac3 |
histone deacetylase 3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC3 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
affects stability multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 affects the stability of HIF1A protein Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Buthionine Sulfoximine promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Dithiothreitol inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein] |
CTD |
PMID:17658243 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein; [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] ochratoxin A inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 protein |
CTD |
PMID:11078701 PMID:15618017 PMID:15994020 PMID:19136476 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
multiple interactions increases activity |
ISO |
HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of HSF1 protein |
CTD |
PMID:15618017 PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HSPB1 protein |
CTD |
PMID:16299251 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases expression decreases secretion |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IFNG protein |
CTD |
PMID:12847270 PMID:16844232 PMID:19888466 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA] |
CTD |
PMID:14998300 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression decreases activity |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in decreased abundance of Prostaglandins]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1B protein [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with IL1B protein] results in decreased secretion of IL1B protein 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of IL1B protein |
CTD |
PMID:11457450 PMID:12604364 PMID:14998300 PMID:15751073 PMID:16461118 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
decreases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1RN mRNA |
CTD |
PMID:15751073 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; [Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2] |
CTD |
PMID:23688403 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:12604364 PMID:12847270 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified inhibits the reaction [INS protein results in increased secretion of Glucose]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of INS mRNA] |
CTD |
PMID:14625208 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA] |
CTD |
PMID:12847270 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]] |
CTD |
PMID:12847270 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein] |
CTD |
PMID:11457450 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Klf6 |
KLF transcription factor 6 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein] |
CTD |
PMID:16611854 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Lep |
leptin |
multiple interactions increases secretion |
ISO |
[Dexamethasone co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased secretion of LEP protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased secretion of LEP protein |
CTD |
PMID:11092516 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] |
CTD |
PMID:19922793 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of LPL mRNA |
CTD |
PMID:12021203 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK1 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK1 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11687581 PMID:12083801 PMID:16611854 PMID:19888466 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK3 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11687581 PMID:12083801 PMID:16611854 PMID:19888466 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Med1 |
mediator complex subunit 1 |
multiple interactions |
ISO |
MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein] |
CTD |
PMID:16324150 |
|
NCBI chr10:83,145,538...83,189,260
Ensembl chr10:83,145,568...83,189,299
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Dactinomycin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA] |
CTD |
PMID:19136476 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of MMP9 mRNA] |
CTD |
PMID:19997048 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MTOR protein |
CTD |
PMID:16611854 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nes |
nestin |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NES protein |
CTD |
PMID:15212945 |
|
NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased activity of NFE2L2 protein; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of NFE2L2 protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and affects the localization of NFE2L2 protein; manganese chloride inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NFE2L2 protein] |
CTD |
PMID:19136476 PMID:21728338 PMID:22245093 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases localization |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased localization of NFKB1 protein |
CTD |
PMID:11457450 PMID:16299251 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased degradation of NFKBIA protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:15498850 PMID:22245093 PMID:23688403 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases activity decreases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS2 protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA] |
CTD |
PMID:11457450 PMID:11890746 PMID:12847270 PMID:15684285 PMID:15994020 PMID:16461118 PMID:19997048 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases activity |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS3 protein |
CTD |
PMID:11890746 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
affects activity multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 affects the activity of NR3C1 protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Dexamethasone binds to NR3C1 protein] |
CTD |
PMID:15187150 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Park7 |
Parkinsonism associated deglycase |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 protein] |
CTD |
PMID:22245093 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of PARP1 protein [delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of PARP1 protein |
CTD |
PMID:15498850 PMID:23973622 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PCK1 mRNA |
CTD |
PMID:9518257 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Plin1 |
perilipin 1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PLIN1 mRNA |
CTD |
PMID:34323617 |
|
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARA protein [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARA mRNA |
CTD |
PMID:9013583 PMID:34323617 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARD protein |
CTD |
PMID:17341418 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects expression decreases response to substance increases expression increases activity multiple interactions decreases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 affects the expression of PPARG PPARG protein mutant form results in decreased susceptibility to 15-deoxy-delta(12,14)-prostaglandin J2 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of PPARG mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein] 15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased expression of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in decreased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased localization of and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [deoxynivalenol results in increased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of PPARG mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARG mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; MG 262 promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PPARG protein |
CTD |
PMID:9013583 PMID:10662598 PMID:11030710 PMID:12065695 PMID:12604364 PMID:12839938 PMID:12847270 PMID:14625208 PMID:14979731 PMID:14998300 PMID:15212945 PMID:15254749 PMID:15322177 PMID:15491415 PMID:15707588 PMID:15729575 PMID:15866424 PMID:15994020 PMID:16324150 PMID:16499875 PMID:17341418 PMID:18278065 PMID:18485432 PMID:19922793 PMID:23943857 PMID:26172262 PMID:30138673 More...
|
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in increased expression of PTEN protein |
CTD |
PMID:16611854 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein] |
CTD |
PMID:12721327 PMID:16256979 |
|
NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
PTGS1 protein promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2] |
CTD |
PMID:17439952 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PTGS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PTGS2 |
CTD |
PMID:11457450 PMID:12604364 PMID:15254749 PMID:19997048 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn11 |
protein tyrosine phosphatase, non-receptor type 11 |
increases phosphorylation |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of PTPN11 protein |
CTD |
PMID:12584205 |
|
NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of and results in decreased phosphorylation of RAF1 protein |
CTD |
PMID:12083801 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RARB |
CTD |
PMID:12839938 PMID:15254749 |
|
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of and results in decreased expression of RB1 protein |
CTD |
PMID:15729575 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases activity |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased activity of RELA protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of RELA protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride affects the localization of RELA protein] |
CTD |
PMID:11457450 PMID:15498850 PMID:20174873 PMID:22245093 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rig1 |
RNA sensor RIG-1 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of RIGI mRNA] |
CTD |
PMID:16303604 |
|
NCBI chr 5:55,321,229...55,369,947
Ensembl chr 5:55,321,235...55,370,819
|
|
G |
Rps6ka1 |
ribosomal protein S6 kinase A1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of RPS6KA1 protein |
CTD |
PMID:16611854 |
|
NCBI chr 5:146,079,018...146,118,272
Ensembl chr 5:146,079,021...146,118,272
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein] |
CTD |
PMID:16611854 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of RUNX2 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Rxra |
retinoid X receptor alpha |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RXRA |
CTD |
PMID:15254749 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]] |
CTD |
PMID:18278065 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] |
CTD |
PMID:19429239 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of SOCS1 mRNA |
CTD |
PMID:12584205 |
|
NCBI chr10:4,882,651...4,884,342
Ensembl chr10:4,882,560...4,884,383
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of SOCS3 mRNA |
CTD |
PMID:12584205 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of SPP1 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [peroxyvanadate results in increased phosphorylation of STAT1 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]] |
CTD |
PMID:12584205 PMID:12847270 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT3 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:12584205 PMID:12847270 PMID:19922793 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tbxa2r |
thromboxane A2 receptor |
multiple interactions decreases expression |
ISO |
PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form] |
CTD |
PMID:16499875 |
|
NCBI chr 7:8,383,347...8,390,753
Ensembl chr 7:8,383,378...8,388,176
|
|
G |
Tg |
thyroglobulin |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TG protein |
CTD |
PMID:11078701 |
|
NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases expression decreases response to substance |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TGFB1 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [alitretinoin results in decreased expression of TGFB1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased susceptibility to TGFB1 protein |
CTD |
PMID:16611854 PMID:18278065 PMID:19429239 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TH protein |
CTD |
PMID:15212945 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TLR2 mRNA |
CTD |
PMID:20174873 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TNF protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:12604364 PMID:19888466 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein] |
CTD |
PMID:11078701 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein] |
CTD |
PMID:23688403 |
|
NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of VIM |
CTD |
PMID:15254749 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Wnt10b |
Wnt family member 10B |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of WNT10B mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 7:129,922,088...129,927,892
Ensembl chr 7:129,922,088...129,927,892
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of XIAP protein |
CTD |
PMID:15498850 PMID:16299251 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:15578100 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases response to substance affects localization |
ISO |
BAX results in increased susceptibility to 16,16-Dimethylprostaglandin E2 16,16-Dimethylprostaglandin E2 affects the localization of BAX protein |
CTD |
PMID:15578100 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:15578100 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
increases activity |
ISO |
16,16-Dimethylprostaglandin E2 results in increased activity of HPGD protein |
CTD |
PMID:14736730 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased activity of MPO protein] |
CTD |
PMID:11686837 PMID:11855677 PMID:11991626 PMID:18306037 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]; 16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA] |
CTD |
PMID:11686837 PMID:11855677 PMID:11991626 PMID:15610444 PMID:18306037 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
Flurbiprofen inhibits the reaction [16,16-Dimethylprostaglandin E2 results in increased expression of PTGS2 mRNA] 16,16-Dimethylprostaglandin E2 inhibits the reaction [SC 560 results in increased expression of PTGS2 mRNA] |
CTD |
PMID:9099957 PMID:15610444 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
16,16-Dimethylprostaglandin E2 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF] |
CTD |
PMID:9298541 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
cyclopentenone results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:18383863 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
cyclopentenone results in increased expression of CDKN1B |
CTD |
PMID:16061222 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO |
cyclopentenone results in decreased phosphorylation of RB1 protein |
CTD |
PMID:16061222 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
multiple interactions |
ISO |
[HSD17B2 protein results in increased metabolism of and results in decreased activity of 2-methoxyestradiol] which results in increased chemical synthesis of 2-methoxyestrone |
CTD |
PMID:16397246 |
|
NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
|
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
28-deoxonimbolide results in increased activity of CASP3 protein |
CTD |
PMID:21381696 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
28-deoxonimbolide results in increased activity of CASP8 protein |
CTD |
PMID:21381696 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
28-deoxonimbolide results in increased activity of CASP9 protein |
CTD |
PMID:21381696 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to AKT1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:19407222 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [ARRB1 protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of ARRB1 protein |
CTD |
PMID:19407222 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Axin1 |
axin 1 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [AXIN1 protein binds to CTNNB1 protein] |
CTD |
PMID:19407222 |
|
NCBI chr10:15,163,684...15,215,615
Ensembl chr10:15,163,684...15,215,615
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of BAD protein |
CTD |
PMID:19407222 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased expression of BAX protein |
CTD |
PMID:19407222 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of BCL2 protein |
CTD |
PMID:19407222 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAD protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [BAX protein binds to BCL2L1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of BCL2L1 protein |
CTD |
PMID:19407222 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased cleavage of and results in increased activity of CASP3 protein AH 23848 inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased cleavage of CASP3 protein] |
CTD |
PMID:19407222 PMID:32115946 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [AXIN1 protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [GSK3B protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased degradation of CTNNB1 protein |
CTD |
PMID:19407222 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein] |
CTD |
PMID:20678559 PMID:28571770 |
|
NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein] |
CTD |
PMID:20093341 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of EGFR protein |
CTD |
PMID:19407222 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of EGR1 protein |
CTD |
PMID:19407222 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of FOS protein |
CTD |
PMID:19407222 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to AKT1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] promotes the reaction [GSK3B protein binds to CTNNB1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:19407222 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of IL1R1 protein |
CTD |
PMID:19407222 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of JUN protein |
CTD |
PMID:19407222 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein] |
CTD |
PMID:28571770 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:19407222 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [GSK3B protein binds to MAPK1 protein binds to MAPK3 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:19407222 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of MYC protein |
CTD |
PMID:19407222 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of NFKB1 protein |
CTD |
PMID:19407222 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:19407222 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in increased cleavage of and results in increased activity of PARP1 protein |
CTD |
PMID:19407222 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER2 protein binds to SRC protein] |
CTD |
PMID:19407222 |
|
NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER4 protein binds to SRC protein] |
CTD |
PMID:19407222 |
|
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein] |
CTD |
PMID:20678559 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of and results in decreased expression of RELA protein |
CTD |
PMID:19407222 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of SP1 protein |
CTD |
PMID:19407222 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [ARRB1 protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [EGFR protein modified form binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER2 protein binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [PTGER4 protein binds to SRC protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased phosphorylation of SRC protein |
CTD |
PMID:19407222 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Tcf7 |
transcription factor 7 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TCF7 protein |
CTD |
PMID:19407222 |
|
NCBI chr10:36,423,443...36,454,350
Ensembl chr10:36,423,445...36,453,535
|
|
G |
Tcf7l2 |
transcription factor 7 like 2 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TCF7L2 protein |
CTD |
PMID:19407222 |
|
NCBI chr 1:254,785,956...254,978,967
Ensembl chr 1:254,786,091...254,978,967
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
AH 23848 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF] |
CTD |
PMID:9298541 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to TNFRSF1A protein]; [6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] results in decreased expression of TNFRSF1A protein |
CTD |
PMID:19407222 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
azadiradione results in increased activity of CASP3 protein |
CTD |
PMID:21381696 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
azadiradione results in increased activity of CASP8 protein |
CTD |
PMID:21381696 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
azadiradione results in increased activity of CASP9 protein |
CTD |
PMID:21381696 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
increases expression |
ISO |
azadiradione results in increased expression of HSPA1A mRNA |
CTD |
PMID:30309986 |
|
NCBI chr20:3,870,765...3,873,221
|
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of ADRA1B protein |
CTD |
PMID:28790194 |
|
NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919
|
|
G |
Adra2c |
adrenoceptor alpha 2C |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of ADRA2C protein |
CTD |
PMID:28790194 |
|
NCBI chr14:75,471,143...75,472,846
Ensembl chr14:75,471,143...75,472,846
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:27417254 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Anxa1 |
annexin A1 |
affects expression |
ISO |
bardoxolone methyl affects the expression of ANXA1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of ARG1 mRNA] |
CTD |
PMID:26918785 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Aurkb |
aurora kinase B |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of AURKB protein |
CTD |
PMID:28790194 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of AVPR1A protein |
CTD |
PMID:28790194 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
B4galt1 |
beta-1,4-galactosyltransferase 1 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of B4GALT1 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 5:55,935,614...55,982,461
Ensembl chr 5:55,935,615...55,982,461
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of BBC3 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased expression of BDNF protein] |
CTD |
PMID:27417254 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of BIRC3 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of CACNA1C protein |
CTD |
PMID:28790194 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
bardoxolone methyl results in decreased expression of CASP8 protein |
CTD |
PMID:25246272 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL11 protein] |
CTD |
PMID:26918785 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL2 protein] bardoxolone methyl results in increased expression of CCL2 mRNA |
CTD |
PMID:26918785 PMID:35724838 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of CCL20 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL3 protein] |
CTD |
PMID:26918785 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL4 protein] |
CTD |
PMID:26918785 |
|
NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CCL5 protein] |
CTD |
PMID:26918785 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
multiple interactions |
ISO |
bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of CCR5 mRNA] |
CTD |
PMID:26918785 |
|
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
|
|
G |
Cd163 |
CD163 molecule |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of CD163 mRNA]; bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of CD163 protein] |
CTD |
PMID:26918785 |
|
NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of CHRM1 protein |
CTD |
PMID:28790194 |
|
NCBI chr 1:205,567,046...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of CHRM2 protein |
CTD |
PMID:28790194 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Clec10a |
C-type lectin domain containing 10A |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of CLEC10A mRNA] |
CTD |
PMID:26918785 |
|
NCBI chr10:54,876,244...54,880,439
Ensembl chr10:54,876,260...54,880,435
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of CXCL1 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of CXCL2 protein] bardoxolone methyl results in increased expression of CXCL2 mRNA |
CTD |
PMID:26918785 PMID:35724838 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of CXCL1 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of DDIT3 protein |
CTD |
PMID:35724838 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
affects expression |
ISO |
bardoxolone methyl affects the expression of DNAJB1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr19:24,522,717...24,526,458
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Drd1 |
dopamine receptor D1 |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of DRD1 protein |
CTD |
PMID:28790194 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of DRD2 protein |
CTD |
PMID:28790194 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Edn1 |
endothelin 1 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of EDN1 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
affects expression |
ISO |
bardoxolone methyl affects the expression of EGLN3 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
bardoxolone methyl results in decreased expression of FASN mRNA |
CTD |
PMID:20372807 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fmo2 |
flavin containing dimethylaniline monoxygenase 2 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of FMO2 mRNA |
CTD |
PMID:25056779 |
|
NCBI chr13:75,221,149...75,244,377
Ensembl chr13:75,224,402...75,244,308
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of and results in decreased phosphorylation of FOXO1 protein] |
CTD |
PMID:27417254 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
affects expression |
ISO |
bardoxolone methyl affects the expression of GADD45A mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression decreases expression |
ISO |
bardoxolone methyl results in increased expression of GCLC mRNA; bardoxolone methyl results in increased expression of GCLC protein bardoxolone methyl results in decreased expression of GCLC mRNA |
CTD |
PMID:27480280 PMID:34480604 PMID:35724838 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression decreases expression |
ISO |
bardoxolone methyl results in increased expression of GCLM; bardoxolone methyl results in increased expression of GCLM mRNA bardoxolone methyl results in decreased expression of GCLM mRNA |
CTD |
PMID:21723306 PMID:34480604 PMID:35724838 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
affects expression |
ISO |
bardoxolone methyl affects the expression of GPX2 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation |
ISO |
GSK3B protein mutant form inhibits the reaction [bardoxolone methyl results in increased expression of HMOX1 protein]; GSK3B protein mutant form inhibits the reaction [bardoxolone methyl results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:25246272 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
decreases expression |
ISO |
bardoxolone methyl results in decreased expression of GSTA1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of GSTP1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression increases expression |
ISO |
GSK3B protein mutant form inhibits the reaction [bardoxolone methyl results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [bardoxolone methyl results in increased expression of HMOX1 protein] bardoxolone methyl results in decreased expression of HMOX1 mRNA bardoxolone methyl results in increased expression of HMOX1 mRNA; bardoxolone methyl results in increased expression of HMOX1 protein [bardoxolone methyl co-treated with aristolochic acid I] results in increased expression of HMOX1 mRNA; bardoxolone methyl promotes the reaction [aristolochic acid I results in increased expression of HMOX1 protein] |
CTD |
PMID:21289052 PMID:24530882 PMID:25246272 PMID:28790194 PMID:34480604 PMID:35724838 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hrh1 |
histamine receptor H 1 |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of HRH1 protein |
CTD |
PMID:28790194 |
|
NCBI chr 4:147,564,781...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases activity |
ISO |
bardoxolone methyl results in increased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of HSPA5 protein |
CTD |
PMID:35724838 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of HTR2A protein |
CTD |
PMID:28790194 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Htr2c |
5-hydroxytryptamine receptor 2C |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of HTR2C protein |
CTD |
PMID:28790194 |
|
NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; bardoxolone methyl inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:35724838 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [IFNG protein results in increased expression of NOS2] |
CTD |
PMID:17363558 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL10 protein]; bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA] |
CTD |
PMID:26918785 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL17A protein] |
CTD |
PMID:26918785 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [IL1B protein affects the localization of NFKBIA protein]; bardoxolone methyl inhibits the reaction [IL1B protein affects the localization of RELA protein]; bardoxolone methyl inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; bardoxolone methyl inhibits the reaction [IL1B protein results in increased expression of TNFAIP3 protein] |
CTD |
PMID:35724838 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
affects expression |
ISO |
bardoxolone methyl affects the expression of IL1R1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of IL6 protein]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein] |
CTD |
PMID:26918785 PMID:27417254 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:28790194 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irf5 |
interferon regulatory factor 5 |
multiple interactions |
ISO |
bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of IRF5 mRNA] |
CTD |
PMID:26918785 |
|
NCBI chr 4:58,127,577...58,140,665
Ensembl chr 4:58,127,640...58,139,267
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased phosphorylation of JAK2 protein] |
CTD |
PMID:27417254 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
increases expression decreases expression multiple interactions |
ISO |
bardoxolone methyl results in increased expression of KEAP1 protein bardoxolone methyl results in decreased expression of KEAP1 mRNA bardoxolone methyl inhibits the reaction [aristolochic acid I results in increased expression of KEAP1 protein] |
CTD |
PMID:24530882 PMID:27358234 PMID:35724838 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased susceptibility to LEP protein]; bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of LEP protein] |
CTD |
PMID:27417254 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of LIF protein] |
CTD |
PMID:26918785 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Mafg |
MAF bZIP transcription factor G |
affects expression decreases expression |
ISO |
bardoxolone methyl affects the expression of MAFG mRNA bardoxolone methyl results in decreased expression of MAFG mRNA |
CTD |
PMID:34480604 PMID:35724838 |
|
NCBI chr10:105,903,307...105,911,845
Ensembl chr10:105,903,237...105,912,026
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of MRC1 protein] |
CTD |
PMID:26918785 |
|
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions increases localization decreases response to substance increases activity |
ISO EXP |
bardoxolone methyl results in increased expression of NFE2L2 mRNA; bardoxolone methyl results in increased expression of NFE2L2 protein bardoxolone methyl inhibits the reaction [aristolochic acid I results in decreased expression of and affects the localization of NFE2L2 protein]; bardoxolone methyl inhibits the reaction [aristolochic acid I results in decreased expression of NFE2L2 mRNA] bardoxolone methyl results in increased localization of NFE2L2 protein NFE2L2 gene mutant form results in decreased susceptibility to bardoxolone methyl bardoxolone methyl results in increased expression of and affects the localization of NFE2L2 protein; NFE2L2 promotes the reaction [bardoxolone methyl results in increased expression of SRXN1 protein]; NFE2L2 protein affects the reaction [bardoxolone methyl results in increased expression of HMOX1 protein] bardoxolone methyl results in increased activity of NFE2L2 protein |
CTD |
PMID:21289052 PMID:21723306 PMID:24530882 PMID:24798383 PMID:25246272 PMID:27358234 PMID:27633142 PMID:28790194 PMID:35724838 More...
|
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased expression of NFKBIA protein] bardoxolone methyl inhibits the reaction [IL1B protein affects the localization of NFKBIA protein]; bardoxolone methyl inhibits the reaction [TNF protein affects the localization of NFKBIA protein] |
CTD |
PMID:25637688 PMID:35724838 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbie |
NFKB inhibitor epsilon |
increases expression |
ISO |
bardoxolone methyl results in increased expression of NFKBIE mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 9:15,443,600...15,450,437
Ensembl chr 9:15,436,941...15,450,437
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [IFNG protein results in increased expression of NOS2] |
CTD |
PMID:17363558 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression decreases expression increases activity multiple interactions |
ISO |
bardoxolone methyl results in increased expression of NQO1 mRNA; bardoxolone methyl results in increased expression of NQO1 protein bardoxolone methyl results in decreased expression of NQO1 mRNA bardoxolone methyl results in increased activity of NQO1 protein [bardoxolone methyl co-treated with aristolochic acid I] results in increased expression of NQO1 mRNA; [bardoxolone methyl co-treated with aristolochic acid I] results in increased expression of NQO1 protein |
CTD |
PMID:24530882 PMID:27480280 PMID:28790194 PMID:34480604 PMID:35724838 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of OLR1 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Oprk1 |
opioid receptor, kappa 1 |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of OPRK1 protein |
CTD |
PMID:28790194 |
|
NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of OPRM1 protein |
CTD |
PMID:28790194 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
bardoxolone methyl results in increased cleavage of PARP1 protein |
CTD |
PMID:17363558 PMID:25246272 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pde4b |
phosphodiesterase 4B |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of PDE4B protein |
CTD |
PMID:28790194 |
|
NCBI chr 5:116,799,827...117,367,707
Ensembl chr 5:116,799,971...117,367,696
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
increases expression |
ISO |
bardoxolone methyl results in increased expression of PDGFB mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression |
ISO |
bardoxolone methyl results in increased expression of PLAU mRNA |
CTD |
PMID:35724838 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
bardoxolone methyl results in increased expression of PPARG mRNA; bardoxolone methyl results in increased expression of PPARG protein |
CTD |
PMID:21289052 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkag2 |
protein kinase AMP-activated non-catalytic subunit gamma 2 |
affects expression |
ISO |
bardoxolone methyl affects the expression of PRKAG2 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 4:10,010,574...10,252,152
Ensembl chr 4:10,010,890...10,252,142
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of PTPN1 protein] |
CTD |
PMID:27417254 |
|
NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504
|
|
G |
Rara |
retinoic acid receptor, alpha |
affects expression |
ISO |
bardoxolone methyl affects the expression of RARA mRNA |
CTD |
PMID:34480604 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [IL1B protein affects the localization of RELA protein]; bardoxolone methyl inhibits the reaction [TNF protein affects the localization of RELA protein] |
CTD |
PMID:35724838 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:28790194 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
affects expression |
ISO |
bardoxolone methyl affects the expression of SCARB1 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Sh3bp5 |
SH3-domain binding protein 5 |
affects expression |
ISO |
bardoxolone methyl affects the expression of SH3BP5 mRNA |
CTD |
PMID:34480604 |
|
NCBI chr16:6,583,462...6,678,344
Ensembl chr16:6,583,465...6,698,975
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
decreases expression |
ISO |
bardoxolone methyl results in decreased expression of SLC3A2 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of SLC47A1 mRNA; bardoxolone methyl results in increased expression of SLC47A1 protein |
CTD |
PMID:27480280 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of SOCS3 mRNA] |
CTD |
PMID:26918785 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sqstm1 |
sequestosome 1 |
affects expression decreases expression |
ISO |
bardoxolone methyl affects the expression of SQSTM1 mRNA bardoxolone methyl results in decreased expression of SQSTM1 mRNA |
CTD |
PMID:34480604 PMID:35724838 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression decreases expression multiple interactions |
ISO |
bardoxolone methyl results in increased expression of SRXN1 protein bardoxolone methyl results in decreased expression of SRXN1 mRNA bardoxolone methyl results in increased expression of SRXN1 mRNA; bardoxolone methyl results in increased expression of SRXN1 protein NFE2L2 promotes the reaction [bardoxolone methyl results in increased expression of SRXN1 protein] |
CTD |
PMID:27358234 PMID:34480604 PMID:35724838 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases phosphorylation |
ISO |
[bardoxolone methyl co-treated with Dietary Fats] results in decreased expression of STAT3 protein; bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of STAT3 protein] bardoxolone methyl results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:17363558 PMID:25637688 PMID:27417254 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tacr1 |
tachykinin receptor 1 |
decreases activity |
ISO |
bardoxolone methyl results in decreased activity of TACR1 protein |
CTD |
PMID:28790194 |
|
NCBI chr 4:114,920,844...115,089,733
Ensembl chr 4:114,920,844...115,089,733
|
|
G |
Tap1 |
transporter 1, ATP binding cassette subfamily B member |
increases expression |
ISO |
bardoxolone methyl results in increased expression of TAP1 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased phosphorylation of TH protein] |
CTD |
PMID:25637688 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Thrsp |
thyroid hormone responsive |
decreases expression |
ISO |
bardoxolone methyl results in decreased expression of THRSP mRNA |
CTD |
PMID:20372807 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [TNF protein affects the localization of NFKBIA protein]; bardoxolone methyl inhibits the reaction [TNF protein affects the localization of RELA protein]; bardoxolone methyl inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; bardoxolone methyl inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] [bardoxolone methyl co-treated with Dietary Fats] results in decreased expression of TNF protein; bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of TNF protein]; bardoxolone methyl inhibits the reaction [Dietary Fats results in increased expression of TNF]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; bardoxolone methyl promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:25637688 PMID:26612656 PMID:26918785 PMID:27417254 PMID:35724838 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
increases expression multiple interactions |
ISO |
bardoxolone methyl results in increased expression of TNFAIP3 mRNA; bardoxolone methyl results in increased expression of TNFAIP3 protein bardoxolone methyl inhibits the reaction [IL1B protein results in increased expression of TNFAIP3 protein]; bardoxolone methyl inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein] |
CTD |
PMID:35724838 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of TNFRSF9 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
decreases expression |
ISO |
bardoxolone methyl results in decreased expression of TRIB3 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression decreases expression |
ISO |
bardoxolone methyl results in increased expression of TXNRD1 mRNA bardoxolone methyl results in decreased expression of TXNRD1 mRNA |
CTD |
PMID:34480604 PMID:35724838 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO |
bardoxolone methyl inhibits the reaction [Dietary Fats results in decreased expression of UCP2 protein] |
CTD |
PMID:25637688 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression |
ISO |
bardoxolone methyl results in increased expression of VCAM1 mRNA |
CTD |
PMID:35724838 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions decreases expression |
ISO |
bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of VEGFA protein]; bardoxolone methyl inhibits the reaction [Lipopolysaccharides results in increased expression of VEGFA mRNA] bardoxolone methyl results in decreased expression of VEGFA mRNA |
CTD |
PMID:26918785 PMID:35724838 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Zfand2a |
zinc finger AN1-type containing 2A |
affects expression decreases expression |
ISO |
bardoxolone methyl affects the expression of ZFAND2A mRNA bardoxolone methyl results in decreased expression of ZFAND2A mRNA |
CTD |
PMID:34480604 PMID:35724838 |
|
NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677
|
|
|
G |
Calml5 |
calmodulin-like 5 |
increases expression |
ISO |
beta-damascenone results in increased expression of CALM4 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr17:66,394,433...66,395,390
|
|
G |
Casp14 |
caspase 14 |
increases expression affects localization |
ISO |
beta-damascenone results in increased expression of CASP14 mRNA beta-damascenone affects the localization of CASP14 protein |
CTD |
PMID:22982537 |
|
NCBI chr 7:10,929,759...10,932,591
Ensembl chr 7:10,926,725...10,933,405
|
|
G |
Ces3a |
carboxylesterase 3a |
increases expression |
ISO |
beta-damascenone results in increased expression of CES3 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr19:32,992,386...33,000,562
|
|
G |
Clca1 |
chloride channel accessory 1 |
increases expression |
ISO |
beta-damascenone results in increased expression of CLCA1 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369
|
|
G |
Clca2 |
chloride channel accessory 2 |
increases expression |
ISO |
beta-damascenone results in increased expression of CLCA2 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 2:233,993,619...234,022,691
Ensembl chr 2:233,995,078...234,022,199
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
ISO |
beta-damascenone results in increased expression of CYP17A1 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Fcgbp |
Fc gamma binding protein |
increases expression |
ISO |
beta-damascenone results in increased expression of FCGBP mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 1:83,374,979...83,413,083
Ensembl chr 1:83,372,127...83,413,083
|
|
G |
Flg |
filaggrin |
increases expression |
ISO |
beta-damascenone results in increased expression of FLG mRNA; beta-damascenone results in increased expression of FLG protein |
CTD |
PMID:22982537 |
|
NCBI chr 2:178,888,688...178,912,731
|
|
G |
Hrnr |
hornerin |
increases expression |
ISO |
beta-damascenone results in increased expression of HRNR mRNA |
CTD |
PMID:22982537 |
|
|
|
G |
Il20ra |
interleukin 20 receptor subunit alpha |
increases expression |
ISO |
beta-damascenone results in increased expression of IL20RA mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 1:14,424,215...14,494,226
Ensembl chr 1:14,451,228...14,493,602
|
|
G |
Il36rn |
interleukin 36 receptor antagonist |
increases expression |
ISO |
beta-damascenone results in increased expression of IL36RN mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 3:7,044,419...7,051,016
Ensembl chr 3:7,044,406...7,051,016
|
|
G |
Krt1 |
keratin 1 |
increases expression |
ISO |
beta-damascenone results in increased expression of KRT1 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Krt10 |
keratin 10 |
increases expression |
ISO |
beta-damascenone results in increased expression of KRT10 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701
|
|
G |
Lce1d |
late cornified envelope 1D |
increases expression |
ISO |
beta-damascenone results in increased expression of LCE1D mRNA |
CTD |
PMID:22982537 |
|
|
|
G |
Lce1f |
late cornified envelope 1F |
increases expression |
ISO |
beta-damascenone results in increased expression of LCE1F mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 2:178,305,786...178,307,372
Ensembl chr 2:178,305,786...178,307,372
|
|
G |
Lipm |
lipase, family member M |
increases expression |
ISO |
beta-damascenone results in increased expression of LIPM mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 1:231,618,145...231,637,599
Ensembl chr 1:231,618,284...231,637,410
|
|
G |
Loricrin |
loricrin cornified envelope precursor protein |
increases expression |
ISO |
beta-damascenone results in increased expression of LOR mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 2:177,558,062...177,559,980
Ensembl chr 2:177,558,252...177,559,807
|
|
G |
Otop3 |
otopetrin 3 |
increases expression |
ISO |
beta-damascenone results in increased expression of OTOP3 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr10:100,577,346...100,588,729
Ensembl chr10:100,577,392...100,588,726
|
|
G |
Pla2g4f |
phospholipase A2, group IVF |
increases expression |
ISO |
beta-damascenone results in increased expression of PLA2G4F mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 3:107,249,053...107,266,201
Ensembl chr 3:107,250,075...107,264,689
|
|
G |
Plcxd1 |
phosphatidylinositol-specific phospholipase C, X domain containing 1 |
increases expression |
ISO |
beta-damascenone results in increased expression of PLCXD1 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr12:46,578,917...46,582,181
Ensembl chr12:46,579,225...46,582,392
|
|
G |
Sdr16c5 |
short chain dehydrogenase/reductase family 16C, member 5 |
increases expression |
ISO |
beta-damascenone results in increased expression of SDR16C5 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 5:17,018,813...17,043,974
Ensembl chr 5:17,018,813...17,040,970
|
|
G |
Susd2 |
sushi domain containing 2 |
increases expression |
ISO |
beta-damascenone results in increased expression of SUSD2 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr20:13,017,468...13,024,903
Ensembl chr20:13,017,477...13,024,903
|
|
G |
Tmprss4 |
transmembrane serine protease 4 |
increases expression |
ISO |
beta-damascenone results in increased expression of TMPRSS4 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 8:45,475,819...45,508,409
Ensembl chr 8:45,476,053...45,508,409
|
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
affects expression |
ISO |
Camphor analog affects the expression of COL1A2 mRNA |
CTD |
PMID:24704097 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
EXP |
Camphor results in decreased activity of CYP2B1 protein |
CTD |
PMID:9242356 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
Camphor inhibits the reaction [CYP2B6 protein results in increased hydrolysis of Bupropion] |
CTD |
PMID:18611395 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Camphor binds to and results in increased activity of ESR1 protein |
CTD |
PMID:27633901 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
ISO |
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
ISO |
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
ISO |
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,376,805...26,463,680
Ensembl chr10:26,374,694...26,464,346
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Camphor inhibits the reaction [cinnamaldehyde results in increased activity of MPO protein] |
CTD |
PMID:21466812 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Camphor binds to and results in decreased activity of PGR protein |
CTD |
PMID:27633901 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
affects expression |
ISO |
Camphor analog affects the expression of RUNX2 mRNA |
CTD |
PMID:24704097 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
affects expression |
ISO |
Camphor analog affects the expression of SPARC mRNA |
CTD |
PMID:24704097 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
Lidocaine promotes the reaction [Camphor results in increased activity of TRPV1 protein] |
CTD |
PMID:18172555 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Trpv3 |
transient receptor potential cation channel, subfamily V, member 3 |
increases activity multiple interactions |
ISO |
Camphor results in increased activity of TRPV3 protein isopentenyl pyrophosphate inhibits the reaction [Camphor results in increased activity of TRPV3 protein] |
CTD |
PMID:21353389 |
|
NCBI chr10:57,883,546...57,915,865
Ensembl chr10:57,883,546...57,913,296
|
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
multiple interactions |
ISO EXP |
cyclohexanone promotes the reaction [2-dichlorobenzene results in increased activity of GLUD1 protein] |
CTD |
PMID:2554539 |
|
NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
cyclohexanone binds to and results in decreased activity of PGR protein |
CTD |
PMID:27633901 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
|
G |
Or5d18 |
olfactory receptor family 5 subfamily D member 18 |
multiple interactions |
ISO |
Cyclohexanones binds to and results in increased activity of OR5D18 protein |
CTD |
PMID:21142015 |
|
NCBI chr 3:73,516,522...73,517,463
Ensembl chr 3:73,516,364...73,519,858 Ensembl chr 3:73,516,364...73,519,858
|
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases reduction multiple interactions |
ISO |
AKR1C1 protein results in increased reduction of cyclopentanone NADP promotes the reaction [AKR1C1 protein results in increased reduction of cyclopentanone] |
CTD |
PMID:23261716 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
multiple interactions increases reduction |
ISO |
[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone] |
CTD |
PMID:23261716 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions increases reduction |
ISO |
[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone] |
CTD |
PMID:23261716 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
|
G |
Adm |
adrenomedullin |
increases expression |
ISO |
diphenylcyclopropenone results in increased expression of ADM mRNA |
CTD |
PMID:25236440 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Ankrd37 |
ankyrin repeat domain 37 |
increases expression |
ISO |
diphenylcyclopropenone results in increased expression of ANKRD37 mRNA |
CTD |
PMID:25236440 |
|
NCBI chr16:46,269,025...46,271,971
Ensembl chr16:46,268,443...46,271,963
|
|
G |
Cdk12 |
cyclin-dependent kinase 12 |
decreases expression |
ISO |
diphenylcyclopropenone results in decreased expression of CDK12 mRNA |
CTD |
PMID:25236440 |
|
NCBI chr10:83,201,177...83,256,906 NCBI chr10:83,267,332...83,280,881
Ensembl chr10:83,201,211...83,280,888
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
decreases expression |
ISO |
diphenylcyclopropenone results in decreased expression of DNMT3B mRNA |
CTD |
PMID:25236440 |
|
NCBI chr 3:142,130,592...142,169,124
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
diphenylcyclopropenone results in increased expression of FOS mRNA |
CTD |
PMID:25236440 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
diphenylcyclopropenone results in increased expression of FOSL1 mRNA |
CTD |
PMID:25236440 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
diphenylcyclopropenone results in increased expression of HMOX1 mRNA |
CTD |
PMID:20491607 PMID:25236440 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Maff |
MAF bZIP transcription factor F |
increases expression |
ISO |
diphenylcyclopropenone results in increased expression of MAFF mRNA |
CTD |
PMID:20491607 |
|
NCBI chr 7:110,912,499...110,923,851
Ensembl chr 7:110,912,499...110,923,851
|
|
G |
Mt1 |
metallothionein 1 |
increases expression |
ISO |
diphenylcyclopropenone results in increased expression of MT1A mRNA |
CTD |
PMID:20491607 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
|
|
G |
Mt2A |
metallothionein 2A |
increases expression |
ISO |
diphenylcyclopropenone results in increased expression of MT2A mRNA |
CTD |
PMID:20491607 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Rbm5 |
RNA binding motif protein 5 |
decreases expression |
ISO |
diphenylcyclopropenone results in decreased expression of RBM5 mRNA |
CTD |
PMID:25236440 |
|
NCBI chr 8:108,420,220...108,449,481
Ensembl chr 8:108,420,222...108,449,430
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
ISO |
diphenylcyclopropenone results in increased expression of SRXN1 mRNA |
CTD |
PMID:25236440 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Stc2 |
stanniocalcin 2 |
decreases expression |
ISO |
diphenylcyclopropenone results in decreased expression of STC2 mRNA |
CTD |
PMID:25236440 |
|
NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
ISO |
diphenylcyclopropenone results in increased expression of TXN mRNA |
CTD |
PMID:20491607 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
fenchone binds to and results in decreased activity of NR3C1 protein |
CTD |
PMID:27633901 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
fenchone binds to and results in decreased activity of PPARG protein |
CTD |
PMID:27633901 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Glycyrrhetinic Acid inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin] |
CTD |
PMID:16904803 PMID:24380838 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB4 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC1 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
Glycyrrhetinic Acid inhibits the reaction [ABCC2 protein results in increased transport of estradiol-17 beta-glucuronide] |
CTD |
PMID:18436619 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ABCC3 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide] |
CTD |
PMID:18436619 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCG5 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ACAT2 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Monocrotaline results in increased expression of ACTA2 protein] |
CTD |
PMID:31325423 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
decreases activity |
ISO |
Glycyrrhetinic Acid results in decreased activity of AKR1C1 protein |
CTD |
PMID:12604236 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
decreases activity |
ISO |
Glycyrrhetinic Acid results in decreased activity of AKR1C2 protein |
CTD |
PMID:12604236 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
affects activity decreases activity |
ISO |
18alpha-glycyrrhetinic acid affects the activity of AKR1C3 protein Glycyrrhetinic Acid results in decreased activity of AKR1C3 protein |
CTD |
PMID:11165023 PMID:12604236 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein binds to and affects the transport of Glycyrrhetinic Acid |
CTD |
PMID:8831264 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ATF6 mRNA] |
CTD |
PMID:35699857 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ATP8B1 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of BAX]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of BAX protein] 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of BAX protein] |
CTD |
PMID:28414158 PMID:31325423 PMID:35699857 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in decreased expression of BCL2]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of BCL2 protein] |
CTD |
PMID:28414158 PMID:31325423 PMID:35699857 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of CASP3] |
CTD |
PMID:35699857 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of CAT mRNA] |
CTD |
PMID:23341968 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of CDKN1B protein] |
CTD |
PMID:31325423 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]] |
CTD |
PMID:10460758 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP1A2 protein |
CTD |
PMID:21800547 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP2E1 protein |
CTD |
PMID:21800547 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of EIF2AK3 mRNA] |
CTD |
PMID:35699857 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of ERN1 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ERN1 mRNA] |
CTD |
PMID:29444456 PMID:35699857 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GGT1 protein] |
CTD |
PMID:28414158 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GPT protein] 18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein] |
CTD |
PMID:28414158 PMID:28549656 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of GPX2 mRNA] |
CTD |
PMID:23341968 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:28414158 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
decreases expression |
ISO |
Glycyrrhetinic Acid results in decreased expression of HRAS protein |
CTD |
PMID:19958823 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
decreases activity |
ISO |
18alpha-glycyrrhetinic acid results in decreased activity of HSD11B1 protein |
CTD |
PMID:24135201 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases activity multiple interactions |
ISO |
18alpha-glycyrrhetinic acid results in decreased activity of HSD11B2 protein Glycyrrhetinic Acid inhibits the reaction [tributyltin results in increased activity of HSD11B2 protein]; Glycyrrhetinic Acid inhibits the reaction [triphenyltin chloride results in increased activity of HSD11B2 protein] |
CTD |
PMID:24135201 PMID:31927052 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
[Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of HSPA5 mRNA] |
CTD |
PMID:35699857 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]] Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of IL1B protein] |
CTD |
PMID:10460758 PMID:23373965 PMID:28414158 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA] |
CTD |
PMID:21644799 PMID:23373965 PMID:24849676 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521
|
|
G |
Irak3 |
interleukin-1 receptor-associated kinase 3 |
multiple interactions increases expression |
ISO |
[Glycyrrhetinic Acid co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IRAK3 mRNA; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]] Glycyrrhetinic Acid results in increased expression of IRAK3 protein |
CTD |
PMID:28213090 |
|
NCBI chr 7:55,653,949...55,714,371
Ensembl chr 7:55,653,962...55,713,121
|
|
G |
Ly96 |
lymphocyte antigen 96 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of MAP3K5 protein] |
CTD |
PMID:29444456 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:23373965 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23373965 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA] |
CTD |
PMID:24613819 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of MTTP mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression |
ISO EXP |
[Glycyrrhetinic Acid results in increased expression of NFE2L2] which results in decreased susceptibility to Carbon Tetrachloride; Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride affects the localization of NFE2L2 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein] |
CTD |
PMID:23341968 PMID:28414158 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein] |
CTD |
PMID:24613819 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of NFKBIA protein] |
CTD |
PMID:23373965 PMID:24613819 PMID:28213090 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein] |
CTD |
PMID:21644799 PMID:23373965 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of NPC1L1 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
glycyrrhetinic acid inhibits the reaction [1-naphthyl isothiocyanate decreases expression of Nr1h4 mRNA in liver] |
RGD |
PMID:30061734 |
RGD:15092071 |
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of BAX protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of CDKN1B protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of BCL2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:31325423 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
decreases activity |
ISO |
18alpha-glycyrrhetinic acid results in decreased activity of PIK3CD protein |
CTD |
PMID:21644799 |
|
NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
decreases activity |
ISO |
18alpha-glycyrrhetinic acid results in decreased activity of PIK3CG protein |
CTD |
PMID:21644799 |
|
NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG protein] |
CTD |
PMID:28414158 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:31325423 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein] |
CTD |
PMID:21644799 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein] Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein] |
CTD |
PMID:23373965 PMID:24613819 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
decreases activity |
ISO |
Glycyrrhetinic Acid results in decreased activity of REN protein |
CTD |
PMID:20460744 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA protein] |
CTD |
PMID:31325423 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 protein] |
CTD |
PMID:31325423 |
|
NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571
|
|
G |
Rock2 |
Rho-associated coiled-coil containing protein kinase 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 protein] |
CTD |
PMID:31325423 |
|
NCBI chr 6:39,679,116...39,774,033
Ensembl chr 6:39,679,082...39,774,031
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Slc51b |
solute carrier family 51 subunit beta |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLC51B mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 8:65,931,891...65,934,893
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLCO1A4 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Sod3 |
superoxide dismutase 3 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of SOD3 mRNA] |
CTD |
PMID:23341968 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of TNF protein] 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:21644799 PMID:24613819 PMID:28213090 PMID:28414158 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA] |
CTD |
PMID:24613819 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of XBP1 protein alternative form] |
CTD |
PMID:29444456 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
ISO |
hyperforin results in increased expression of ABCB1; hyperforin results in increased expression of ABCB1 mRNA hyperforin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir] |
CTD |
PMID:15266218 PMID:16005588 PMID:24259679 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
increases expression |
ISO |
hyperforin results in increased expression of ALAS1 mRNA |
CTD |
PMID:24259679 |
|
NCBI chr 8:106,876,514...106,889,852
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
ISO |
hyperforin results in increased expression of BAK1 protein |
CTD |
PMID:32485087 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression increases expression multiple interactions |
EXP ISO |
hyperforin results in decreased expression of BAX mRNA hyperforin results in increased expression of BAX protein hyperforin inhibits the reaction [aluminum maltolate results in increased expression of BAX mRNA] |
CTD |
PMID:30481499 PMID:32485087 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
hyperforin inhibits the reaction [aluminum maltolate results in decreased expression of BCL2 mRNA] hyperforin results in increased expression of BCL2 mRNA |
CTD |
PMID:30481499 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage decreases expression |
ISO EXP |
hyperforin inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; hyperforin inhibits the reaction [aluminum maltolate results in increased expression of CASP3 mRNA] hyperforin results in increased cleavage of CASP3 protein hyperforin results in decreased expression of CASP3 mRNA |
CTD |
PMID:30481499 PMID:32485087 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases cleavage |
ISO |
hyperforin results in increased cleavage of CASP8 protein |
CTD |
PMID:32485087 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
hyperforin results in decreased expression of CCND1 protein |
CTD |
PMID:32485087 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression |
ISO |
hyperforin results in decreased expression of CFLAR protein |
CTD |
PMID:32485087 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions decreases expression |
EXP ISO |
hyperforin inhibits the reaction [aluminum maltolate results in increased expression of CYCS protein] hyperforin results in decreased expression of CYCS protein |
CTD |
PMID:30481499 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
ISO |
hyperforin inhibits the reaction [CYP1A1 protein affects the metabolism of benzo(a)pyrene 7,8-dihydrodiol] hyperforin results in decreased activity of CYP1A1 protein |
CTD |
PMID:14633740 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
increases expression |
ISO |
hyperforin results in increased expression of CYP24A1 mRNA |
CTD |
PMID:15630458 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
hyperforin results in increased expression of CYP2B6 mRNA |
CTD |
PMID:24259679 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression multiple interactions decreases activity |
ISO |
hyperforin results in increased expression of CYP3A4; hyperforin results in increased expression of CYP3A4 mRNA hyperforin results in increased expression of and results in increased activity of CYP3A4 protein hyperforin results in decreased activity of CYP3A4 protein |
CTD |
PMID:15100173 PMID:15266218 PMID:16005588 PMID:16442130 PMID:17954527 PMID:24259679 More...
|
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
ISO |
hyperforin results in increased expression of CYP3A5 mRNA |
CTD |
PMID:24259679 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
hyperforin results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:24259679 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases phosphorylation |
ISO |
hyperforin results in decreased phosphorylation of EGFR protein |
CTD |
PMID:32485087 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
hyperforin results in increased expression of FAS protein |
CTD |
PMID:32485087 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
hyperforin results in increased expression of FASLG protein |
CTD |
PMID:32485087 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
hyperforin results in increased expression of ICAM1 mRNA |
CTD |
PMID:15622447 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
hyperforin promotes the reaction [JUN protein binds to CXCL8 promoter] |
CTD |
PMID:15622447 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation decreases phosphorylation |
ISO |
hyperforin results in increased phosphorylation of MAPK1 protein hyperforin results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:15622447 PMID:32485087 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation decreases phosphorylation |
ISO |
hyperforin results in increased phosphorylation of MAPK3 protein hyperforin results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:15622447 PMID:32485087 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
hyperforin results in decreased expression of MCL1 protein |
CTD |
PMID:32485087 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases response to substance affects binding increases activity |
ISO |
[NR1I2 protein co-treated with hyperforin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to hyperforin] which results in decreased expression of SLC22A1 mRNA; hyperforin binds to and results in increased activity of NR1I2 protein; hyperforin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]; NR1I2 protein affects the reaction [hyperforin results in increased expression of CYP2C9 mRNA]; NR1I2 protein promotes the reaction [hyperforin results in increased abundance of Lipids] hyperforin binds to NR1I2 protein hyperforin results in increased activity of NR1I2 protein |
CTD |
PMID:14600250 PMID:15630458 PMID:15856409 PMID:20079722 PMID:26187274 PMID:26920453 PMID:27071811 More...
|
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression |
ISO |
hyperforin results in increased expression of POR mRNA |
CTD |
PMID:24259679 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
decreases expression multiple interactions |
ISO |
hyperforin results in decreased expression of SLC22A1 protein [NR1I2 protein co-treated with hyperforin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to hyperforin] which results in decreased expression of SLC22A1 mRNA; hyperforin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA] |
CTD |
PMID:26920453 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression |
ISO |
hyperforin results in increased expression of UGT1A1 mRNA |
CTD |
PMID:24259679 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
hyperforin results in decreased expression of XIAP protein |
CTD |
PMID:32485087 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
increases response to substance |
ISO |
ERCC6 mutant form results in increased susceptibility to irofulven |
CTD |
PMID:28076683 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity |
ISO |
irofulven results in decreased activity of GSR protein |
CTD |
PMID:19668867 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
EXP |
Ketamine results in increased expression of ABCA1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
ABCB1A protein affects the susceptibility to [Pentobarbital co-treated with Ketamine] |
CTD |
PMID:17959987 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
EXP |
Ketamine results in increased expression of ABCG1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abhd16a |
abhydrolase domain containing 16A, phospholipase |
increases expression |
EXP |
Ketamine results in increased expression of ABHD16A mRNA |
CTD |
PMID:20080153 |
|
NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927
|
|
G |
Abhd5 |
abhydrolase domain containing 5, lysophosphatidic acid acyltransferase |
decreases expression |
EXP |
Ketamine results in decreased expression of ABHD5 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 8:122,000,241...122,026,447
Ensembl chr 8:122,000,389...122,026,447
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
decreases expression |
EXP |
Ketamine results in decreased expression of ACAT2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Acbd3 |
acyl-CoA binding domain containing 3 |
decreases expression |
EXP |
Ketamine results in decreased expression of ACBD3 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr13:92,455,813...92,484,556
Ensembl chr13:92,455,655...92,483,380
|
|
G |
Acbd5 |
acyl-CoA binding domain containing 5 |
decreases expression |
EXP |
Ketamine results in decreased expression of ACBD5 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr17:85,206,178...85,248,909
Ensembl chr17:85,206,303...85,248,215
|
|
G |
Ace |
angiotensin I converting enzyme |
increases expression |
EXP |
Ketamine results in increased expression of ACE mRNA |
CTD |
PMID:20080153 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Acp6 |
acid phosphatase 6, lysophosphatidic |
decreases expression |
EXP |
Ketamine results in decreased expression of ACP6 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 2:184,711,975...184,733,067
Ensembl chr 2:184,711,619...184,733,017
|
|
G |
Acr |
acrosin |
increases expression |
EXP |
Ketamine results in increased expression of ACR mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 7:120,636,581...120,644,474
Ensembl chr 7:120,638,321...120,644,474
|
|
G |
Acsbg1 |
acyl-CoA synthetase bubblegum family member 1 |
increases expression |
EXP |
Ketamine results in increased expression of ACSBG1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 8:54,991,294...55,047,276
Ensembl chr 8:54,991,296...55,047,391
|
|
G |
Actg2 |
actin gamma 2, smooth muscle |
decreases expression |
EXP |
Ketamine results in decreased expression of ACTG2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:116,021,832...116,046,475
Ensembl chr 4:116,021,832...116,046,465
|
|
G |
Acvr1c |
activin A receptor type 1C |
decreases expression |
EXP |
Ketamine results in decreased expression of ACVR1C mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 3:42,815,490...42,892,423
Ensembl chr 3:42,822,610...42,892,327
|
|
G |
Adap2 |
ArfGAP with dual PH domains 2 |
increases expression |
EXP |
Ketamine results in increased expression of ADAP2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr10:65,138,006...65,166,147
Ensembl chr10:65,138,020...65,165,604
|
|
G |
Adck2 |
aarF domain containing kinase 2 |
decreases expression |
EXP |
Ketamine results in decreased expression of ADCK2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:68,348,853...68,362,725
Ensembl chr 4:68,348,864...68,374,608
|
|
G |
Adcy8 |
adenylate cyclase 8 |
decreases expression |
EXP |
Ketamine results in decreased expression of ADCY8 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 7:96,417,310...96,665,911
Ensembl chr 7:96,417,324...96,665,911
|
|
G |
Adcy9 |
adenylate cyclase 9 |
increases expression |
EXP |
Ketamine results in increased expression of ADCY9 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr10:11,138,966...11,262,067
Ensembl chr10:11,139,446...11,262,066
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of ADCYAP1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Add2 |
adducin 2 |
decreases expression |
EXP |
Ketamine results in decreased expression of ADD2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:118,444,594...118,538,505
Ensembl chr 4:118,497,416...118,538,505
|
|
G |
Adgrb2 |
adhesion G protein-coupled receptor B2 |
increases expression |
EXP |
Ketamine results in increased expression of ADGRB2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 5:142,299,190...142,362,540
Ensembl chr 5:142,331,329...142,362,540
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
EXP |
Ketamine results in increased expression of AFP mRNA |
CTD |
PMID:20080153 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agt |
angiotensinogen |
decreases expression increases expression |
ISO EXP |
Ketamine results in decreased expression of AGT protein Ketamine results in increased expression of AGT mRNA |
CTD |
PMID:6349867 PMID:20080153 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtrap |
angiotensin II receptor-associated protein |
increases expression |
EXP |
Ketamine results in increased expression of AGTRAP mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036
|
|
G |
Ahr |
aryl hydrocarbon receptor |
decreases expression |
EXP |
Ketamine results in decreased expression of AHR mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
decreases expression multiple interactions |
EXP |
Ketamine results in decreased expression of AIF1 mRNA Cannabidiol inhibits the reaction [Ketamine results in decreased expression of AIF1 mRNA] |
CTD |
PMID:31823199 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Akap9 |
A-kinase anchoring protein 9 |
decreases expression |
EXP |
Ketamine results in decreased expression of AKAP9 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:30,056,738...30,192,716
Ensembl chr 4:30,056,738...30,192,606
|
|
G |
Alb |
albumin |
increases expression |
EXP |
Ketamine results in increased expression of ALB mRNA |
CTD |
PMID:20080153 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
decreases expression |
EXP |
Ketamine results in decreased expression of ALDH18A1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 1:239,375,657...239,407,967
Ensembl chr 1:239,375,669...239,407,890
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
increases expression |
EXP |
Ketamine results in increased expression of ALDOC mRNA |
CTD |
PMID:20080153 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alms1 |
ALMS1, centrosome and basal body associated protein |
decreases expression |
EXP |
Ketamine results in decreased expression of ALMS1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:118,125,581...118,226,005
Ensembl chr 4:118,125,607...118,226,005
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
decreases expression |
EXP |
Ketamine results in decreased expression of AMIGO2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695
|
|
G |
Anapc1 |
anaphase promoting complex subunit 1 |
increases expression |
EXP |
Ketamine results in increased expression of ANAPC1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 3:115,850,117...115,930,259
Ensembl chr 3:115,850,185...115,930,273
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
EXP |
Ketamine results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Ankrd42 |
ankyrin repeat domain 42 |
decreases expression |
EXP |
Ketamine results in decreased expression of ANKRD42 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 1:146,648,080...146,691,086
Ensembl chr 1:146,648,080...146,691,108
|
|
G |
Anxa11 |
annexin A11 |
increases expression |
EXP |
Ketamine results in increased expression of ANXA11 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr16:1,412,373...1,457,814
Ensembl chr16:1,410,756...1,457,797
|
|
G |
Anxa3 |
annexin A3 |
decreases expression |
EXP |
Ketamine results in decreased expression of ANXA3 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617
|
|
G |
Anxa4 |
annexin A4 |
increases expression |
EXP |
Ketamine results in increased expression of ANXA4 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Anxa5 |
annexin A5 |
decreases expression |
EXP |
Ketamine results in decreased expression of ANXA5 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Ap2m1 |
adaptor related protein complex 2 subunit mu 1 |
multiple interactions |
ISO |
Ketamine inhibits the reaction [NTRK2 protein binds to AP2M1 protein] |
CTD |
PMID:31631060 |
|
NCBI chr11:80,355,307...80,364,218
Ensembl chr11:80,328,041...80,364,140
|
|
G |
Ap3m1 |
adaptor related protein complex 3 subunit mu 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of AP3M1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr15:3,246,616...3,264,846
Ensembl chr15:3,246,926...3,264,844
|
|
G |
Ap5m1 |
adaptor related protein complex 5 subunit mu 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of AP5M1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr15:22,355,478...22,385,222
Ensembl chr15:22,355,500...22,377,750
|
|
G |
Apex2 |
apurinic/apyrimidinic endodeoxyribonuclease 2 |
decreases expression |
EXP |
Ketamine results in decreased expression of APEX2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr X:19,425,684...19,508,459
Ensembl chr X:19,487,419...19,508,439
|
|
G |
Aplf |
aprataxin and PNKP like factor |
decreases expression |
EXP |
Ketamine results in decreased expression of APLF mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:120,070,471...120,122,656
Ensembl chr 4:120,070,471...120,122,633
|
|
G |
Apmap |
adipocyte plasma membrane associated protein |
increases expression |
EXP |
Ketamine results in increased expression of APMAP mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 3:139,409,020...139,437,296
Ensembl chr 3:139,409,022...139,437,341
|
|
G |
Apoe |
apolipoprotein E |
decreases response to substance increases expression |
ISO EXP |
APOE results in decreased susceptibility to Ketamine Ketamine results in increased expression of APOE mRNA |
CTD |
PMID:9778666 PMID:20080153 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
increases expression multiple interactions |
ISO |
Ketamine results in increased expression of APP mRNA Ketamine results in decreased expression of and results in increased cleavage of APP protein; Monensin inhibits the reaction [Ketamine results in decreased expression of and results in increased cleavage of APP protein] [Ketamine results in increased cleavage of APP protein] which results in increased abundance of amyloid beta-protein (1-40); [Ketamine results in increased cleavage of APP protein] which results in increased abundance of amyloid beta-protein (1-42); Ketamine results in decreased expression of and results in increased cleavage of APP protein; Monensin inhibits the reaction [[Ketamine results in increased cleavage of APP protein] which results in increased abundance of amyloid beta-protein (1-40)]; Monensin inhibits the reaction [[Ketamine results in increased cleavage of APP protein] which results in increased abundance of amyloid beta-protein (1-42)] |
CTD |
PMID:35378374 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Appbp2 |
amyloid beta precursor protein binding protein 2 |
decreases expression |
EXP |
Ketamine results in decreased expression of APPBP2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr10:70,057,774...70,099,877
Ensembl chr10:70,057,774...70,099,835
|
|
G |
Arfgef1 |
ADP ribosylation factor guanine nucleotide exchange factor 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of ARFGEF1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 5:8,982,061...9,076,326
Ensembl chr 5:8,981,540...9,076,326
|
|
G |
Arhgap5 |
Rho GTPase activating protein 5 |
decreases expression |
EXP |
Ketamine results in decreased expression of ARHGAP5 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 6:69,975,904...70,039,299
Ensembl chr 6:69,976,214...70,037,660
|
|
G |
Arih1 |
ariadne RBR E3 ubiquitin protein ligase 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of ARIH1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 8:59,777,378...59,879,762
Ensembl chr 8:59,777,379...59,880,245
|
|
G |
Arl6 |
ADP-ribosylation factor like GTPase 6 |
decreases expression |
EXP |
Ketamine results in decreased expression of ARL6 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr11:40,711,878...40,738,254
Ensembl chr11:40,712,022...40,737,937
|
|
G |
Arl6ip6 |
ADP ribosylation factor like GTPase 6 interacting protein 6 |
decreases expression |
EXP |
Ketamine results in decreased expression of ARL6IP6 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 3:37,689,994...37,720,358
Ensembl chr 3:37,690,382...37,718,018
|
|
G |
Armc10 |
armadillo repeat containing 10 |
decreases expression |
EXP |
Ketamine results in decreased expression of ARMC10 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:13,399,004...13,414,594
Ensembl chr 4:13,395,207...13,414,548
|
|
G |
Art3 |
ADP-ribosyltransferase 3 |
increases expression |
EXP |
Ketamine results in increased expression of ART3 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr14:15,637,230...15,719,442
Ensembl chr14:15,637,237...15,665,407
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of ASCL1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 7:21,904,153...21,906,003
Ensembl chr 7:21,903,126...21,905,993
|
|
G |
Asic4 |
acid sensing ion channel subunit family member 4 |
increases expression |
EXP |
Ketamine results in increased expression of ASIC4 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 9:76,941,532...76,962,900
Ensembl chr 9:76,941,532...76,962,900
|
|
G |
Aspdh |
aspartate dehydrogenase domain containing |
increases expression |
EXP |
Ketamine results in increased expression of ASPDH mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 1:94,956,327...94,960,722
Ensembl chr 1:94,958,316...94,960,722
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
Ketamine results in increased expression of ATF4 mRNA |
CTD |
PMID:35728656 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
ISO |
Ketamine results in increased expression of ATF6 mRNA |
CTD |
PMID:35728656 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atg12 |
autophagy related 12 |
increases expression |
EXP |
Ketamine results in increased expression of ATG12 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418
|
|
G |
Atp13a4 |
ATPase 13A4 |
increases expression |
EXP |
Ketamine results in increased expression of ATP13A4 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr11:71,222,196...71,359,933
Ensembl chr11:71,226,161...71,359,933
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
EXP |
Ketamine results in increased expression of ATP1A1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp1a2 |
ATPase Na+/K+ transporting subunit alpha 2 |
increases expression |
EXP |
Ketamine results in increased expression of ATP1A2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
increases expression |
EXP |
Ketamine results in increased expression of ATP1A3 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Atp6v0a1 |
ATPase H+ transporting V0 subunit a1 |
increases expression |
EXP |
Ketamine results in increased expression of ATP6V0A1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr10:85,935,802...85,989,901
Ensembl chr10:85,935,854...85,989,895
|
|
G |
Atp6v1c2 |
ATPase H+ transporting V1 subunit C2 |
increases expression |
EXP |
Ketamine results in increased expression of ATP6V1C2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 6:40,080,545...40,144,199
Ensembl chr 6:40,080,547...40,120,028
|
|
G |
Atp7a |
ATPase copper transporting alpha |
decreases expression |
EXP |
Ketamine results in decreased expression of ATP7A mRNA |
CTD |
PMID:20080153 |
|
NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354
|
|
G |
B4gat1 |
beta-1,4-glucuronyltransferase 1 |
increases expression |
EXP |
Ketamine results in increased expression of B4GAT1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 1:202,343,268...202,345,490
Ensembl chr 1:202,343,240...202,346,065
|
|
G |
Bace1 |
beta-secretase 1 |
increases expression multiple interactions |
ISO |
Ketamine results in increased expression of BACE1 protein Ketamine results in increased expression of and affects the localization of BACE1 protein; Monensin inhibits the reaction [Ketamine results in increased expression of and affects the localization of BACE1 protein] |
CTD |
PMID:35378374 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bag3 |
BAG cochaperone 3 |
increases expression |
EXP |
Ketamine results in increased expression of BAG3 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
|
|
G |
Baiap2 |
BAR/IMD domain containing adaptor protein 2 |
increases expression |
EXP |
Ketamine results in increased expression of BAIAP2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr10:105,223,065...105,290,130
Ensembl chr10:105,223,090...105,290,134
|
|
G |
Banp |
Btg3 associated nuclear protein |
decreases expression |
EXP |
Ketamine results in decreased expression of BANP mRNA |
CTD |
PMID:20080153 |
|
NCBI chr19:50,007,710...50,082,742
Ensembl chr19:50,007,881...50,082,738
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects localization multiple interactions increases expression |
ISO EXP |
Ketamine affects the localization of BAX protein TRPV4 protein affects the reaction [Ketamine results in increased expression of BAX mRNA]; TRPV4 protein affects the reaction [Ketamine results in increased expression of BAX protein] Ketamine results in increased expression of BAX mRNA; Ketamine results in increased expression of BAX protein |
CTD |
PMID:18456338 PMID:19001360 PMID:25937004 PMID:33536391 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bckdha |
branched chain keto acid dehydrogenase E1 subunit alpha |
increases expression |
EXP |
Ketamine results in increased expression of BCKDHA mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 1:81,138,946...81,167,765
Ensembl chr 1:81,138,947...81,167,862
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP |
TRPV4 protein affects the reaction [Ketamine results in decreased expression of BCL2 mRNA]; TRPV4 protein affects the reaction [Ketamine results in decreased expression of BCL2 protein] Ketamine results in decreased expression of BCL2 mRNA; Ketamine results in decreased expression of BCL2 protein |
CTD |
PMID:33536391 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bclaf3 |
BCLAF1 and THRAP3 family member 3 |
decreases expression |
EXP |
Ketamine results in decreased expression of BCLAF3 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr X:35,257,228...35,328,883
Ensembl chr X:35,263,576...35,328,816
|
|
G |
Bcorl1 |
BCL6 co-repressor-like 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of BCORL1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr X:127,516,504...127,584,529
Ensembl chr X:127,537,538...127,584,087
|
|
G |
Bcs1l |
BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone |
decreases expression |
EXP |
Ketamine results in decreased expression of BCS1L mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 9:76,164,925...76,168,940
Ensembl chr 9:76,164,932...76,168,938
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
increases expression |
ISO |
Ketamine results in increased expression of BDKRB1 mRNA; Ketamine results in increased expression of BDKRB1 protein |
CTD |
PMID:27638051 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
EXP ISO |
Ketamine inhibits the reaction [Isoflurophate results in decreased expression of BDNF protein]; Ketamine inhibits the reaction [Pilocarpine results in increased expression of BDNF mRNA] Ketamine results in increased expression of BDNF protein Sirolimus inhibits the reaction [Ketamine results in increased expression of BDNF protein] |
CTD |
PMID:8635431 PMID:32592718 PMID:33022268 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
increases expression |
ISO |
Ketamine results in increased expression of BECN1 protein |
CTD |
PMID:34487425 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bhlhe22 |
basic helix-loop-helix family, member e22 |
decreases expression |
EXP |
Ketamine results in decreased expression of BHLHE22 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 2:100,486,400...100,489,510
Ensembl chr 2:100,486,400...100,489,510
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
increases expression |
EXP |
Ketamine results in increased expression of BHLHE40 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bhlhe41 |
basic helix-loop-helix family, member e41 |
increases expression |
EXP |
Ketamine results in increased expression of BHLHE41 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:178,833,085...178,838,685
Ensembl chr 4:178,834,271...178,838,468
|
|
G |
Bmi1 |
BMI1 proto-oncogene, polycomb ring finger |
decreases expression |
EXP |
Ketamine results in decreased expression of BMI1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
decreases expression |
EXP |
Ketamine results in decreased expression of BNIP3 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
Ketamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of BRAF protein] |
CTD |
PMID:19540866 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Brinp2 |
BMP/retinoic acid inducible neural specific 2 |
increases expression |
EXP |
Ketamine results in increased expression of BRINP2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr13:70,431,006...70,532,766
Ensembl chr13:70,431,010...70,531,810
|
|
G |
Btg1 |
BTG anti-proliferation factor 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of BTG1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 7:31,341,391...31,343,649
Ensembl chr 7:31,341,027...31,343,649
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
decreases expression |
EXP |
Ketamine results in decreased expression of BUB1B mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
|
|
G |
C1qa |
complement C1q A chain |
increases expression |
EXP |
Ketamine results in increased expression of C1QA mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534
|
|
G |
C1qb |
complement C1q B chain |
increases expression |
EXP |
Ketamine results in increased expression of C1QB mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407
|
|
G |
C1qc |
complement C1q C chain |
increases expression multiple interactions decreases expression |
EXP |
Ketamine results in increased expression of C1QC mRNA Cannabidiol inhibits the reaction [Ketamine results in decreased expression of C1QC mRNA] |
CTD |
PMID:20080153 PMID:31823199 |
|
NCBI chr 5:149,127,424...149,130,732
Ensembl chr 5:149,127,415...149,131,017
|
|
G |
C2 |
complement C2 |
increases expression |
EXP |
Ketamine results in increased expression of C2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr20:3,951,474...3,970,376
Ensembl chr20:3,951,474...3,976,505
|
|
G |
C2cd2l |
C2CD2-like |
increases expression |
EXP |
Ketamine results in increased expression of C2CD2L mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 8:44,648,074...44,658,856
Ensembl chr 8:44,648,079...44,658,340
|
|
G |
C2cd4b |
C2 calcium-dependent domain containing 4B |
increases expression |
EXP |
Ketamine results in increased expression of C2CD4B mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 8:68,372,793...68,396,477
Ensembl chr 8:68,384,847...68,396,328
|
|
G |
C4bpb |
complement component 4 binding protein, beta |
increases expression |
EXP |
Ketamine results in increased expression of C4BPB mRNA |
CTD |
PMID:20080153 |
|
NCBI chr13:42,120,798...42,131,515
Ensembl chr13:42,120,798...42,131,817
|
|
G |
Caap1 |
caspase activity and apoptosis inhibitor 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of CAAP1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 5:109,313,253...109,414,323
Ensembl chr 5:109,361,912...109,414,314
|
|
G |
Cabcoco1 |
ciliary associated calcium binding coiled-coil 1 |
increases expression |
EXP |
Ketamine results in increased expression of CABCOCO1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr20:20,058,492...20,167,973
Ensembl chr20:20,058,454...20,167,725
|
|
G |
Cabp7 |
calcium binding protein 7 |
increases expression |
EXP |
Ketamine results in increased expression of CABP7 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr14:79,598,822...79,609,172
Ensembl chr14:79,598,827...79,609,240
|
|
G |
Cacng2 |
calcium voltage-gated channel auxiliary subunit gamma 2 |
increases expression |
EXP |
Ketamine results in increased expression of CACNG2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 7:109,572,838...109,698,516
Ensembl chr 7:109,574,459...109,697,227
|
|
G |
Calb2 |
calbindin 2 |
increases expression |
EXP |
Ketamine results in increased expression of CALB2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438
|
|
G |
Camkk1 |
calcium/calmodulin-dependent protein kinase kinase 1 |
increases expression |
EXP |
Ketamine results in increased expression of CAMKK1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498
|
|
G |
Cand2 |
cullin-associated and neddylation-dissociated 2 (putative) |
decreases expression |
EXP |
Ketamine results in decreased expression of CAND2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:148,835,050...148,864,039
Ensembl chr 4:148,835,053...148,863,153
|
|
G |
Cant1 |
calcium activated nucleotidase 1 |
increases expression |
EXP |
Ketamine results in increased expression of CANT1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr10:103,637,079...103,650,240
Ensembl chr10:103,531,504...103,650,109
|
|
G |
Car4 |
carbonic anhydrase 4 |
increases expression |
EXP |
Ketamine results in increased expression of CAR4 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501
|
|
G |
Car7 |
carbonic anhydrase 7 |
increases expression |
EXP |
Ketamine results in increased expression of CAR7 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr19:429,063...438,478
Ensembl chr19:429,075...438,467
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage multiple interactions increases expression |
ISO EXP |
Ketamine results in increased activity of CASP3 protein Ketamine results in increased cleavage of CASP3 protein TRPV4 protein affects the reaction [Ketamine results in increased cleavage of CASP3 protein]; TRPV4 protein affects the reaction [Ketamine results in increased expression of CASP3 mRNA] Ketamine results in increased expression of CASP3 mRNA; Ketamine results in increased expression of CASP3 protein modified form |
CTD |
PMID:17920787 PMID:19001360 PMID:25937004 PMID:33536391 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
increases activity |
ISO |
Ketamine results in increased activity of CASP6 protein |
CTD |
PMID:19001360 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp9 |
caspase 9 |
increases activity increases expression |
ISO EXP |
Ketamine results in increased activity of CASP9 protein Ketamine results in increased expression of CASP9 mRNA |
CTD |
PMID:19001360 PMID:20080153 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases activity multiple interactions |
EXP |
Ketamine results in decreased activity of CAT protein TRPV4 protein affects the reaction [Ketamine results in decreased activity of CAT protein] |
CTD |
PMID:33536391 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr3 |
carbonyl reductase 3 |
decreases expression |
EXP |
Ketamine results in decreased expression of CBR3 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Cbx1 |
chromobox 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of CBX1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr10:81,770,307...81,789,981
Ensembl chr10:81,770,342...81,791,096
|
|
G |
Cbx7 |
chromobox 7 |
increases expression |
EXP |
Ketamine results in increased expression of CBX7 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 7:111,460,656...111,479,231
Ensembl chr 7:111,460,656...111,477,973
|
|
G |
Ccdc115 |
coiled-coil domain containing 115 |
increases expression |
EXP |
Ketamine results in increased expression of CCDC115 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 9:36,650,384...36,654,348
Ensembl chr 9:36,649,271...36,653,946
|
|
G |
Ccdc50 |
coiled-coil domain containing 50 |
decreases expression |
EXP |
Ketamine results in decreased expression of CCDC50 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr11:73,332,798...73,395,333
Ensembl chr11:73,334,248...73,395,150
|
|
G |
Ccdc85a |
coiled-coil domain containing 85A |
decreases expression |
EXP |
Ketamine results in decreased expression of CCDC85A mRNA |
CTD |
PMID:20080153 |
|
NCBI chr14:102,126,574...102,359,207
Ensembl chr14:102,129,029...102,359,058
|
|
G |
Ccdc90b |
coiled-coil domain containing 90B |
decreases expression |
EXP |
Ketamine results in decreased expression of CCDC90B mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 1:146,632,756...146,646,314
Ensembl chr 1:146,633,036...146,647,338
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of CCL5 mRNA]; [Ketamine co-treated with Atropine] inhibits the reaction [Soman results in increased expression of CCL5 protein] |
CTD |
PMID:22245128 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
EXP |
Ketamine results in decreased expression of CCNA2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
EXP |
Ketamine results in decreased expression of CCND1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccndbp1 |
cyclin D1 binding protein 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of CCNDBP1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 3:107,962,402...107,974,234
Ensembl chr 3:107,962,261...107,974,233
|
|
G |
Ccpg1 |
cell cycle progression 1 |
increases expression |
EXP |
Ketamine results in increased expression of CCPG1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
increases expression |
EXP |
Ketamine results in increased expression of CCR5 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
|
|
G |
Ccsap |
centriole, cilia and spindle-associated protein |
increases expression |
EXP |
Ketamine results in increased expression of CCSAP mRNA |
CTD |
PMID:20080153 |
|
NCBI chr19:51,824,954...51,843,469
Ensembl chr19:51,826,994...51,842,753
|
|
G |
Cd24 |
CD24 molecule |
decreases expression |
EXP |
Ketamine results in decreased expression of CD24 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd38 |
CD38 molecule |
increases expression |
EXP |
Ketamine results in increased expression of CD38 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cd83 |
CD83 molecule |
increases expression |
EXP |
Ketamine results in increased expression of CD83 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cdc42ep3 |
CDC42 effector protein 3 |
decreases expression |
EXP |
Ketamine results in decreased expression of CDC42EP3 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 6:15,710,894...15,731,366
Ensembl chr 6:15,708,730...15,732,721
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
EXP |
Ketamine results in decreased expression of CDC6 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdca7 |
cell division cycle associated 7 |
decreases expression |
EXP |
Ketamine results in decreased expression of CDCA7 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 3:57,322,718...57,333,353
Ensembl chr 3:57,322,708...57,333,353
|
|
G |
Cdh11 |
cadherin 11 |
decreases expression |
EXP |
Ketamine results in decreased expression of CDH11 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr19:2,148,447...2,305,754
Ensembl chr19:2,148,458...2,304,272
|
|
G |
Cdh7 |
cadherin 7 |
decreases expression |
EXP |
Ketamine results in decreased expression of CDH7 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr13:26,672,058...26,821,571
Ensembl chr13:26,672,484...26,819,846
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of CDK1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk14 |
cyclin-dependent kinase 14 |
decreases expression |
EXP |
Ketamine results in decreased expression of CDK14 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:28,666,688...29,258,865
Ensembl chr 4:28,666,843...29,258,861
|
|
G |
Cdnf |
cerebral dopamine neurotrophic factor |
affects expression |
ISO |
Ketamine affects the expression of CDNF mRNA |
CTD |
PMID:35728656 |
|
NCBI chr17:74,714,564...74,728,639
Ensembl chr17:74,713,564...74,728,639
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
EXP |
Ketamine results in increased expression of CEBPB mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cenpc |
centromere protein C |
decreases expression |
EXP |
Ketamine results in decreased expression of CENPC1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr14:21,988,067...22,046,732
Ensembl chr14:21,988,144...22,055,476
|
|
G |
Cep70 |
centrosomal protein 70 |
decreases expression |
EXP |
Ketamine results in decreased expression of CEP70 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 8:99,810,270...99,863,279
Ensembl chr 8:99,810,367...99,862,855
|
|
G |
Cfap126 |
cilia and flagella associated protein 126 |
increases expression |
EXP |
Ketamine results in increased expression of CFAP126 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr13:83,526,657...83,542,552
Ensembl chr13:83,526,657...83,542,552
|
|
G |
Cfap410 |
cilia and flagella associated protein 410 |
increases expression |
EXP |
Ketamine results in increased expression of CFAP410 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr20:10,687,863...10,694,736
Ensembl chr20:10,687,863...10,694,737
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
increases expression |
EXP |
Ketamine results in increased expression of CHI3L1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of CHORDC1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162
|
|
G |
Chpf2 |
chondroitin polymerizing factor 2 |
increases expression |
EXP |
Ketamine results in increased expression of CHPF2 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:10,578,470...10,585,940
Ensembl chr 4:10,580,462...10,585,916
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
ISO |
Ketamine inhibits the reaction [Scopolamine Derivatives binds to CHRM1 protein] |
CTD |
PMID:12456425 |
|
NCBI chr 1:205,567,046...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
multiple interactions |
ISO |
Ketamine inhibits the reaction [Scopolamine Derivatives binds to CHRM2 protein] |
CTD |
PMID:12456425 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
multiple interactions |
ISO |
Ketamine inhibits the reaction [Scopolamine Derivatives binds to CHRM3 protein] |
CTD |
PMID:12456425 |
|
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
G |
Ciao3 |
cytosolic iron-sulfur assembly component 3 |
increases expression |
EXP |
Ketamine results in increased expression of CIAO3 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr10:14,795,888...14,804,953
Ensembl chr10:14,795,961...14,804,950
|
|
G |
Cldn11 |
claudin 11 |
increases expression |
EXP |
Ketamine results in increased expression of CLDN11 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050
|
|
G |
Clec2l |
C-type lectin domain family 2, member L |
increases expression |
EXP |
Ketamine results in increased expression of CLEC2L mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:67,392,118...67,414,539
Ensembl chr 4:67,397,873...67,414,537
|
|
G |
Clec4a3 |
C-type lectin domain family 4, member A3 |
increases expression |
EXP |
Ketamine results in increased expression of CLEC4A3 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 4:156,214,030...156,224,818
Ensembl chr 4:156,214,718...156,224,817
|
|
G |
Clk1 |
CDC-like kinase 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of CLK1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 9:59,947,774...59,959,002
Ensembl chr 9:59,947,764...59,957,000
|
|
G |
Clmp |
CXADR-like membrane protein |
decreases expression |
EXP |
Ketamine results in decreased expression of CLMP mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 8:41,060,527...41,168,841
Ensembl chr 8:41,060,799...41,168,838
|
|
G |
Clu |
clusterin |
increases expression |
EXP |
Ketamine results in increased expression of CLU mRNA |
CTD |
PMID:20080153 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cmtm5 |
CKLF-like MARVEL transmembrane domain containing 5 |
increases expression |
EXP |
Ketamine results in increased expression of CMTM5 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr15:28,412,624...28,415,304
Ensembl chr15:28,412,624...28,415,287
|
|
G |
Cmtm8 |
CKLF-like MARVEL transmembrane domain containing 8 |
increases expression |
EXP |
Ketamine results in increased expression of CMTM8 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 8:114,481,730...114,547,107
Ensembl chr 8:114,481,982...114,547,083
|
|
G |
Cnksr3 |
Cnksr family member 3 |
increases expression |
EXP |
Ketamine results in increased expression of CNKSR3 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 1:43,499,273...43,591,630
Ensembl chr 1:43,499,487...43,591,635
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
decreases expression |
EXP |
Ketamine results in decreased expression of CNR1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Coa4 |
cytochrome c oxidase assembly factor 4 homolog |
decreases expression |
EXP |
Ketamine results in decreased expression of COA4 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 1:154,882,199...154,885,445
Ensembl chr 1:154,882,155...154,888,174
|
|
G |
Coa7 |
cytochrome c oxidase assembly factor 7 |
increases expression |
EXP |
Ketamine results in increased expression of COA7 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 5:123,069,356...123,080,942
Ensembl chr 5:123,069,371...123,080,199
|
|
G |
Cog6 |
component of oligomeric golgi complex 6 |
decreases expression |
EXP |
Ketamine results in decreased expression of COG6 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 2:137,062,127...137,099,176
Ensembl chr 2:137,061,346...137,099,190
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
decreases expression |
EXP |
Ketamine results in decreased expression of COL11A1 mRNA |
CTD |
PMID:20080153 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Commd5 |
COMM domain containing 5 |
increases expression |
EXP |
| |